Mode
Text Size
Log in / Sign up
Phase 4 N=38 Randomized Triple-blind Basic Science

Brain Imaging of Lidoderm for Chronic Back Pain

Low Back Pain

Enrolled (actual)
38
Serious AEs
0.0%
Results posted
Jul 2013
Primary outcome: Primary: Pain Intensity on a Visual Analog Scale (VAS) The Scale Had Values From 0-100, Where 0 Represents "no Pain" and 100 Was the "Worst Pain Imaginable". — 51.0; 51.6 peak pain intensity

Study Design & Population

Study type
Interventional
Phase
Phase 4
Interventions
lidocaine (Drug); placebo (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Northwestern University
Primary completion
Jun 2010

Outcome Measures

OutcomeResultp-value
PRIMARY
Pain Intensity on a Visual Analog Scale (VAS) The Scale Had Values From 0-100, Where 0 Represents "no Pain" and 100 Was the "Worst Pain Imaginable".
51.0; 51.6

Summary

The investigators tested whether pain decrease can be observed centrally with non-invasive brain imaging in CBP subjects receiving Lidoderm. The investigators first tested effects of 5% Lidoderm patched in an open labelled trial. Next the investigators compared the effects of Lidocaine versus Placebo patches. Three time points were evaluated: baseline (before treatment) and 6 hours and 2 weeks after treatment. The latter trial was a 2 arm, double blind, placebo controlled trial, where participants either received Lidoderm or placebo patches, without cross over.

Eligibility Criteria

Inclusion Criteria

  • Male or Female 18 years or older of age
  • Pain in the location of the lower back
  • Pain duration for a minimum of 6 months on a continuous basis
  • Pain intensity of at least 3 out of 10 on most days of the week over the past six months
  • Manifestations of radicular element of pain: radiation below knee (examples towards thigh, buttocks).
  • Right handedness

Exclusion Criteria

  • Applying for or currently receiving workers' compensation or disability status.
  • Back pain secondary to spinal cord injury
  • Back pain secondary to any systemic condition (e.g ankylosing spondylitis0
  • Diabetes mellitus
  • Back pain secondary to tumors.
  • Standard MRI criteria re: claustrophobia, metal objects etc.
  • Subjects with cognitive deficits such as dementia, psychiatric illness including depression with a BDI score of more than 19 (moderate to severe depression), history of brain injury, history of chronic disease
  • Pregnant and/or lactating women
  • Left handedness
  • Active cancer
  • Other serious painful condition (e.g., arthritis)
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01515540). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search